Monitoring Safety & Efficacy of Rare Gene Therapies During Clinical Development & in the Commercial Setting

Time: 11:15 am
day: Day 2 CLINICAL AM


  • Reviewing the potential direct and indirect risks of genetic therapies
  • Implementing safety monitoring before and after approval of bluebird’s gene therapies
  • Long-term follow-up of patients receiving genetic therapies now and in the future